Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enbridge Inc (ENB) vs Smith & Nephew plc (SNN) Price & Performance

Enbridge IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Enbridge Inc vs Smith & Nephew plc — how do they compare? Enbridge Inc trades at $51.72 (market cap $112.62B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Enbridge Inc is far larger — about 9× Smith & Nephew plc's market cap, and Enbridge Inc pays the higher dividend (5.34%). Which is the better fit depends on your goals.

ENBSNN
Market Cap
$112.62B$12.54B
Sector
EnergyHealth
52-Week High
$58.04$38.70
52-Week Low
$45.23$28.73
Enterprise Value
$196.53B$15.57B
Dividend Yield
5.34%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enbridge Inc

ENB trades at $51.49, up 0.19% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company reported Q2 2026 EPS of $0.46, beating estimates of $0.43, and maintains a strong dividend yield with 31 consecutive years of increases. Revenue for 2025 reached $65.19B, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is evenly split between Buy and Hold ratings.

Outlook is stable with growth supported by a $41B project backlog and utility demand, but risks include regulatory challenges like pipeline disputes and high debt levels. The stock offers income appeal through dividends, yet faces headwinds from energy market volatility and legal uncertainties.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

About Enbridge Inc

Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.

Read more on ENB

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN